18F-fluorodeoxyglucose PET/Computed Tomography: Head and Neck Salivary Gland Tumors

Stephen M Broski; Derek R Johnson; Annie T Packard; Christopher H Hunt

doi:10.1016/j.cpet.2021.12.002

¹⁸F-fluorodeoxyglucose PET/Computed Tomography: Head and Neck Salivary Gland Tumors

PET Clin. 2022 Apr;17(2):249-263. doi: 10.1016/j.cpet.2021.12.002. Epub 2022 Feb 26.

Authors

Stephen M Broski¹, Derek R Johnson², Annie T Packard³, Christopher H Hunt²

Affiliations

¹ Department of Radiology, Mayo Clinic, Rochester, MN, USA. Electronic address: Broski.stephen@mayo.edu.
² Department of Radiology, Mayo Clinic, Rochester, MN, USA; Department of Neurology, Mayo Clinic, Rochester, MN, USA.
³ Department of Radiology, Mayo Clinic, Rochester, MN, USA.

PMID: 35232668
DOI: 10.1016/j.cpet.2021.12.002

Abstract

Salivary gland tumors (SGTs) are a heterogeneous group of neoplasms arising from the 3 pairs of major salivary glands (parotid, submandibular, and sublingual) or numerous minor salivary glands located throughout the oral cavity. This review discusses the role of PET/computed tomography (CT) in evaluation of SGTs, including staging, restaging, prognostication, and response assessment. 18F-fluorodeoxyglucose (FDG) PET/CT is useful for staging and restaging malignant SGTs and offers important prognostic information in these patients. It is less useful for differentiating benign and malignant SGTs. Non-FDG PET radiotracers, perineural spread, parotid incidentalomas, and interpretative pitfalls are discussed as well.

Keywords: PET/CT; Prognostic; Salivary gland tumor; Staging.

Publication types

Review

MeSH terms

Fluorodeoxyglucose F18*
Humans
Positron Emission Tomography Computed Tomography / methods
Positron-Emission Tomography
Salivary Gland Neoplasms* / diagnostic imaging
Salivary Gland Neoplasms* / pathology
Salivary Glands / pathology
Tomography, X-Ray Computed

Substances

Fluorodeoxyglucose F18